Xianglin Yuan. Chinese expert consensus on managing thrombocytopenia in patients with cancer and liver injury. Oncol Transl Med, 2023, 9: 1-14.
Chinese expert consensus on managing thrombocytopenia in patients with cancer and liver injury
Received:February 15, 2023  Revised:February 15, 2023
View Full Text  View/Add Comment  Download reader
KeyWord:cancer; liver disease; liver injury; thrombocytopenia; expert consensus
Author NameAffiliationE-mail
Xianglin Yuan Tongji Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology xlyuan@tjh.tjmu.edu.cn 
Hits: 1165
Download times: 1383
Abstract:
      Thrombocytopenia and liver injury are serious clinical problems in patients with cancer. The etiology of thrombocytopenia in patients with cancer and liver injury (TCLI) is complicated. Managing cancer therapy-induced thrombocytopenia has gradually become standardized, and managing liver injury-associated thrombocytopenia has become more effective with the approval and marketing of relevant drugs. However, the optimal strategy for managing thrombocytopenia in patients with cancer and liver injury remains unclear, and the superposition of thrombocytopenia and liver injury further increases the difficulty of cancer treatment. Therefore, the Committee of Cancer Support Therapy of the Chinese Anti-Cancer Association has organized experts to analyze and discuss relevant literature to form a Chinese expert consensus on managing thrombocytopenia in patients with cancer and liver injury (2022 Edition) to guide clinical practice.
Close